Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Eur Urol Oncol. 2020 Mar 10;3(4):544–547. doi: 10.1016/j.euo.2020.02.003

Figure 1.

Figure 1.

A) Kaplan-Meier Analysis of overall survival and disease specific survival among patients with at least one mutation in ATM, RB1, FANCC (Mutant) versus those without a mutation in these genes (Wild Type). All patients received neoadjuvant chemotherapy with a cisplatin backbone (MVAC or Gem/Cis). B) 5-year overall survival (OS) and disease specific survival (DSS) rates for combined and individual cohorts with 95% confidence intervals represented in parenthesis.